Anxiety and Depression Among Gendarmes Posted to French Guiana (TAD-GENDGF)

October 31, 2023 updated by: Direction Centrale du Service de Santé des Armées

Anxiety and Depression Among Gendarmes Posted to French Guiana (TAD-GENDGF)

This is a mixed-method, single-center study involving two concurrent phases: a quantitative phase with an anonymous self-administered questionnaires, and a qualitative phase with individual contextual interviews and a focus group. The hypothesis underlying this study is that isolated postings are a risk factor for anxiety-depressive disorders. The aim of this study is to provide new information to help propose targeted prevention and health promotion measures.

Study Overview

Status

Not yet recruiting

Conditions

Intervention / Treatment

Study Type

Observational

Enrollment (Estimated)

600

Contacts and Locations

This section provides the contact details for those conducting the study, and information on where this study is being conducted.

Study Contact

Study Locations

  • French Guiana
    • Guyane
      • Cayenne, Guyane, French Guiana, 97306
        • DIASS Guyane
        • Contact:
          • DIA
          • Phone Number: 0594395983

Participation Criteria

Researchers look for people who fit a certain description, called eligibility criteria. Some examples of these criteria are a person's general health condition or prior treatments.

Eligibility Criteria

Ages Eligible for Study

  • Adult
  • Older Adult

Accepts Healthy Volunteers

Yes

Sampling Method

Non-Probability Sample

Study Population

healthy volunteer

Description

Inclusion Criteria:

  • Gendarme in active position
  • Age over 18
  • Assignment in French Guiana for more than 6 months at the time of the study
  • Not opting for study participation

Exclusion Criteria:

  • Previously diagnosed psychiatric condition
  • People with a reading/writing disability in the French language
  • Major incapacity

Study Plan

This section provides details of the study plan, including how the study is designed and what the study is measuring.

How is the study designed?

Design Details

What is the study measuring?

Primary Outcome Measures

Outcome Measure
Measure Description
Time Frame
Prevalence of anxiety-depressive disorders according to posting site.
Time Frame: Through study completion (6 months)
Comparison of the prevalence of anxiety-depressive disorders among gendarmes posted to French Guiana according to their posting site.
Through study completion (6 months)

Secondary Outcome Measures

Outcome Measure
Measure Description
Time Frame
Factors associated with the presence of an anxiety-depressive disorder
Time Frame: Through study completion (6 months)
Evaluate factors associated with the presence of an anxiety-depressive disorder, both overall and by type of disorder
Through study completion (6 months)

Collaborators and Investigators

This is where you will find people and organizations involved with this study.

Sponsor

Direction Centrale du Service de Santé des Armées

Study record dates

These dates track the progress of study record and summary results submissions to ClinicalTrials.gov. Study records and reported results are reviewed by the National Library of Medicine (NLM) to make sure they meet specific quality control standards before being posted on the public website.

Study Major Dates

Study Start (Estimated)

November 1, 2023

Primary Completion (Estimated)

October 1, 2024

Study Completion (Estimated)

November 1, 2024

Study Registration Dates

First Submitted

October 26, 2023

First Submitted That Met QC Criteria

October 31, 2023

First Posted (Actual)

November 1, 2023

Study Record Updates

Last Update Posted (Actual)

November 1, 2023

Last Update Submitted That Met QC Criteria

October 31, 2023

Last Verified

October 1, 2023

More Information

Terms related to this study

Additional Relevant MeSH Terms

Other Study ID Numbers

  • 2022PPRC07
  • 2023-100889-36 (Other Identifier: IDRCB)

Plan for Individual participant data (IPD)

Plan to Share Individual Participant Data (IPD)?

UNDECIDED

Drug and device information, study documents

Studies a U.S. FDA-regulated drug product

No

Studies a U.S. FDA-regulated device product

No

This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.

Subscribe